Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
656 Views
eMediNexus 22 December 2017
The US Food and Drug Administration (FDA) has approved Giapreza (angiotensin II) as intravenous infusion to treat dangerously low blood pressure in adults with septic or other distributive shock. Giapreza can cause dangerous blood clots with serious consequences, so, prophylactic treatment for blood clots should be used.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Nuchal Translucency Measurements in Prenatal Screening: Revisiting NT.....
Choosing the Right Fats for a Healthy Life..
Achieving Type 2 Diabetes Remission through Weight Loss: How Much is .....
Sarcopenia: A Harbinger of Cognitive Decline in Postmenopausal Women?..
Integrating Early CKD Detection into Primary Care: A Call for Action i.....